×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Failed uproleselan Phase III AML trial affects GlycoMimetics' future
Clinical Trials Arena
The chance of reviving uproleselan remains slim as Glycomimetics is running short of time and cash to launch another trial.
5 days ago
GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock
Fierce Biotech
GlycoMimetics CEO Harout Semerjian said in March that phase 3 blood cancer data could “fundamentally impact our company's trajectory.
1 week ago
Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
InvestorPlace
GlycoMimetics stock is falling on Monday with heavy trading of GLYC after posting lackluster results from a Phase 3 trial of uproleselan.
1 week ago
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute ...
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for...
1 week ago
GlycoMimetics reports data from Phase III AML treatment trial
MSN
The study did not show a statistically significant improvement in overall survival after treatment with the uproleselan regimen.
3 days ago
GlycoMimetics Shares Drop After Leukemia Treatment Trial Fails to Meet Primary Endpoint
MarketWatch
By Adriano Marchese GlycoMimetics shares were sharply lower in premarket trading on Monday after the company said its drug to treat a form...
1 week ago
Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML
OncLive
Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with...
1 week ago
GlycoMimetics Forges Ahead With Uproleselan In AML After Phase III Failure
Scrip
The company said an NCI trial and a China study remain ongoing despite a Phase III study in relapsed/refractory disease failing,...
1 week ago
Glycomimetics wilts on missed acute myeloid leukemia phase III
BioWorld MedTech
Top-line data from Glycomimetics Inc.'s pivotal phase III study of uproleselan in 388 patients with relapsed/refractory acute myeloid...
1 week ago
GlycoMimetics: Is No News Bad News? (NASDAQ:GLYC)
Seeking Alpha
GlycoMimetics is a biotech company focusing on developing a targeted therapy for acute myeloid leukemia. GLYC's lead candidate, uproleselan,...
2 weeks ago